Why the study?
Does a computerized decision support system improve guideline adherence and reduce costs compared to actual physician prescribing in hypertensive patients?
Does a computerized decision support system improve guideline adherence and reduce costs compared to actual physician prescribing in hypertensive patients?
A computerized decision support system for hypertension management can significantly improve guideline adherence for complex patients while reducing medication costs by 33-40%.
Answers are grounded in this paper and cite their sources.
DSS may improve guideline adherence and lower costs in complex hypertension; leaves open randomized outcome trials.
OBJECTIVE: To evaluate a computerized decision support system (DSS) for drug treatment of hypertension, regarding quality, safety, and cost compared to actual antihypertensive drug treatment. DESIGN: The medical profiles of 338 hypertensive patients treated with drugs against hypertension were processed by the DSS. The drug treatment proposed by the system was then compared to actual treatment given by their physician. SETTING: Four health centres in the county of Västerbotten, in Sweden. SUBJECTS: A list of hypertensive patients was extracted from the computerized medical records of each health centre and every fifth patient's medical profile was assessed by the system. INTERVENTIONS: None. MAIN OUTCOME MEASURES: Drug used, drug used in relation to certain major diseases such as diabetes mellitus, asthma, ischaemic heart disease (IHD), and previous myocardial infarction. Adherence to hypertension guidelines, safety, and cost. RESULTS: The DSS suggested significantly more thiazides and significantly fewer calcium antagonists than the physicians had prescribed, with a total cost reduction of 33-40%, depending on doses chosen. The DSS drug profile was more adherent to guidelines in patients with major complicating diseases, suggesting an improvement in treatment quality for these patients by the DSS. CONCLUSION: The DSS which fully implements current guidelines may improve the quality of antihypertensive treatment, concurrently leading to a considerable reduction in drug costs.
No takes yet. Share an insight, caveat, or question.
Persson et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: